OneSource Specialty Pharma Limited has announced its participation in the Investec India Promoter & Founder Conference 2026, scheduled to take place on March 09, 2026 in Mumbai. The company informed stock exchanges about this investor engagement activity through a regulatory filing dated March 04, 2026.

Conference Participation Details

The pharmaceutical company's representatives will participate in the conference as part of their regular investor engagement activities. The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Discussion Topics and Compliance

During the conference interactions, OneSource Specialty Pharma's representatives will discuss publicly available information with investors and stakeholders. The discussions will focus on several key areas:

• Business overview and current operations
• Strategic initiatives and future plans
• Industry trends and market dynamics
• Growth outlook and opportunities

The company has specifically noted that no unpublished price sensitive information (UPSI) will be shared during these interactions, ensuring full compliance with regulatory guidelines and maintaining transparency standards.

Regulatory Communication

The formal intimation was signed by Trisha A, Company Secretary and Compliance Officer (Membership Number: A47635), and communicated to both major stock exchanges where the company is listed. The filing serves as an official record of the company's participation in this investor engagement activity, maintaining adherence to disclosure requirements under SEBI regulations.

OneSource Specialty Pharma Limited has secured crucial regulatory approval for its ambitious merger plan, receiving no objection letters from both the National Stock Exchange of India Limited and BSE Limited on February 25, 2026. The approval relates to a comprehensive composite scheme of arrangement and amalgamation involving multiple entities that will significantly reshape the company's structure.

Merger Structure and Entities Involved

The proposed scheme encompasses a complex multi-entity merger involving several companies. The arrangement includes the amalgamation of Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, and Strides Pharma Services Private Limited with OneSource Specialty Pharma Limited. This merger by absorption will consolidate operations across multiple jurisdictions, including provisions under both Indian Companies Act and Singapore Companies Act.

SEBI Compliance Requirements

The stock exchange approval comes with extensive compliance obligations mandated by SEBI. The regulatory body has outlined comprehensive disclosure requirements that OneSource must fulfill before proceeding with the merger. Key compliance areas include ensuring adherence to Regulation 11 of SEBI LODR Regulations 2015 and providing detailed information about ongoing legal proceedings against the company, its promoters, and directors.

The company must prominently disclose shareholding pattern changes on the first page of shareholder meeting notices, including pre-scheme and post-scheme shareholding percentages for both promoter groups and public shareholders. Additional requirements include disclosing accumulated losses of transferor entities, impact on reserves, and comprehensive details about the merger's rationale and benefits.

Financial and Operational Disclosures

SEBI has mandated extensive financial disclosures as part of the approval process. OneSource must provide detailed information about assets, liabilities, net worth, and revenue of all companies involved in the merger, both pre and post-scheme implementation. The company is required to disclose the impact on revenue generating capacity and provide comprehensive cost-benefit analysis of the proposed arrangement.

Regulatory Timeline and Next Steps

The no objection letters carry a validity period of six months from February 25, 2026, within which OneSource must submit the scheme to the National Company Law Tribunal. The company has committed to placing these approval letters before the Board of Directors of all involved companies for review and decision on the implementation pathway.

The merger scheme remains subject to several additional approvals, including clearance from Hon'ble National Company Law Tribunal Mumbai, Singapore Court, and approval from respective shareholders and creditors under applicable laws. OneSource must also ensure compliance with various SEBI master circulars and maintain transparency through regular updates on company and stock exchange websites.

Shareholder Communication Requirements

As part of the approval conditions, OneSource must provide comprehensive information to shareholders to enable informed decision-making. This includes detailed explanations of how the merger benefits public shareholders, particularly considering that accumulated losses from transferor entities will become part of OneSource's balance sheet. The company must also disclose potential integration challenges, market conditions, and financial uncertainties associated with the merger.

The stock exchanges have reserved their rights to withdraw approval if any submitted information is found incomplete, incorrect, misleading, or false, or for any contravention of exchange rules and regulations. OneSource has uploaded the approval letters on its website and will continue to provide updates as the merger process progresses through the remaining regulatory approvals.